Vernakalant

Generic Name
Vernakalant
Brand Names
Brinavess
Drug Type
Small Molecule
Chemical Formula
C20H31NO4
CAS Number
794466-70-9
Unique Ingredient Identifier
9G468C8B13
Background

Vernakalant was developed by Cardiome Pharma as as an antiarrhythmic drug intended for rapid conversion of atrial fibrillation to sinus rhythm. It acts as an atypical class III antiarrhythmic drug that potentiates its effect in higher heart rates. Intravenous formulation was approved in Europe in September 2010 as Brinavess and in Canada in April 2017. It is...

Indication

Indicated for the rapid conversion of recent onset of atrial fibrillation to sinus rhythm in adults for non-surgery patients that lasts for less than 7 days of duration and post-cardiac surgery patients with atrial fibrillation lasting less than 3 days of duration.

Associated Conditions
Atrial Fibrillation
Associated Therapies
-
Clinical Trials
Related News

Vernakalant Versus Amiodarone for Post-operative Atrial Fibrillation in Cardiac Surgery Patients

Phase 3
Not yet recruiting
Conditions
Atrial Fibrillation
Post-cardiac Surgery
Interventions
Drug: Amiodarone
Drug: Vernakalant
First Posted Date
2021-02-10
Last Posted Date
2024-05-22
Lead Sponsor
University of Calgary
Target Recruit Count
50
Registration Number
NCT04748991

RAFF4 Trial: Vernakalant vs. Procainamide for Acute Atrial Fibrillation in the Emergency Department

Phase 4
Recruiting
Conditions
Atrial Fibrillation
Interventions
Drug: Procainamide
Drug: Vernakalant
First Posted Date
2020-07-24
Last Posted Date
2023-09-13
Lead Sponsor
Ottawa Hospital Research Institute
Target Recruit Count
340
Registration Number
NCT04485195
Locations
🇨🇦

Kingston Health Sciences Centre, Kingston, Ontario, Canada

🇨🇦

St. Michaels, Toronto, Ontario, Canada

🇨🇦

University of Alberta Hospital, Edmonton, Alberta, Canada

and more 11 locations

Predictive Factors to Effectively Terminate Paroxysmal Atrial Fibrillation by Blocking Atrial Selective Ionic Currents

First Posted Date
2016-12-29
Last Posted Date
2023-08-07
Lead Sponsor
David Filgueiras-Rama
Target Recruit Count
50
Registration Number
NCT03005366
Locations
🇪🇸

Hospital Clínico Universitario San Carlos, Madrid, Madrid/Madrid, Spain

Vernakalant Versus Flecainide: Atrial Contractility

First Posted Date
2012-07-20
Last Posted Date
2012-07-20
Lead Sponsor
Maastricht University Medical Center
Target Recruit Count
70
Registration Number
NCT01646281
Locations
🇳🇱

Maastricht University Hospital, Maastricht, Netherlands

A Study Comparing Vernakalant Therapy to Amiodarone Therapy in Acute Management of Recent Onset Atrial Fibrillation (AF) (MK-6621-055)

Phase 4
Withdrawn
Conditions
Atrial Fibrillation
Interventions
Drug: Vernakalant
Drug: Amiodarone
First Posted Date
2012-06-25
Last Posted Date
2013-08-26
Lead Sponsor
Advanz Pharma
Registration Number
NCT01627106

Study of Normal Conditions of Use, Dosing, and Safety of Intravenous (IV) Administration of Vernakalant (MK-6621-049)

Completed
Conditions
Atrial Fibrillation
Interventions
Drug: Vernakalant
First Posted Date
2011-06-10
Last Posted Date
2019-12-30
Lead Sponsor
Correvio International Sarl
Target Recruit Count
2015
Registration Number
NCT01370629
Locations
🇩🇪

St-Vincenz Krankenhaus, Paderborn, Germany

🇪🇸

Hospital Universitario Severo Ochoa, Madrid, Spain

🇸🇪

Skanes Universistetssjukhus, Malmo, Sweden

and more 2 locations

A Phase 3b Study of Vernakalant Injection in Patients With Recent Onset Symptomatic Atrial Fibrillation (AF)(MK-6621-045)

Phase 3
Terminated
Conditions
Atrial Fibrillation
Interventions
Drug: Placebo
Drug: Vernakalant
First Posted Date
2009-10-02
Last Posted Date
2014-03-10
Lead Sponsor
Advanz Pharma
Target Recruit Count
217
Registration Number
NCT00989001
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy